Breaking News

Clinipace Appoints Medical Director

By Kristin Brooks | February 27, 2014

Schacter to provide strategic guidance for oncology programs

Lee Schacter, Ph.D., MD, FACP, has been appointed executive medical director at Clinipace Worldwide. Dr. Schacter will provide strategic guidance, program design, and medical oversight to clients conducting oncology development programs.
Dr. Schacter was previously an independent consultant with Phasen Consulting, and served as acting chief managing officer of the Multiple Myeloma Research Foundation, worked with Janssen R&D, and served as medical director for marketed oncology products at AstraZeneca. Additionally, he served as senior director of global medical affairs at Pfizer and executive medical director, global head oncology, with MDS Pharma Services, among other positions with Yale School of Medicine, Bristol Myers.
“Coming off a year of significant growth during which we saw our depth and breadth of expertise managing oncology trials remain one of our strongest core competencies, it was critical for us to expand our team of experts in that field,” said Mark Harvill, chief operating officer, Clinipace Worldwide. “Dr. Schacter is a perfect fit as he comes to us as a highly experienced drug development expert, board certified internist, and medical oncologist with extensive experience in development and regulatory strategy.”

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important